State of New Jersey Common Pension Fund D Sells 87 Shares of Glaukos Co. (NYSE:GKOS)

State of New Jersey Common Pension Fund D decreased its holdings in Glaukos Co. (NYSE:GKOS) by 0.4% in the third quarter, HoldingsChannel.com reports. The fund owned 19,418 shares of the medical instruments supplier’s stock after selling 87 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Glaukos were worth $2,530,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. bought a new stake in shares of Glaukos in the 2nd quarter worth about $67,460,000. Primecap Management Co. CA lifted its stake in shares of Glaukos by 43.9% during the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after acquiring an additional 372,180 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after purchasing an additional 246,322 shares during the period. Iron Triangle Partners LP grew its stake in Glaukos by 75.6% in the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after acquiring an additional 184,919 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its stake in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock worth $95,112,000 after purchasing an additional 155,653 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Trading Down 0.3 %

Shares of NYSE:GKOS opened at $143.21 on Thursday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $145.84. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The firm has a market capitalization of $7.90 billion, a P/E ratio of -47.42 and a beta of 1.02. The business’s 50-day moving average is $130.53 and its 200 day moving average is $121.82.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same period in the previous year, the company earned ($0.50) earnings per share. The business’s quarterly revenue was up 23.9% compared to the same quarter last year. On average, research analysts predict that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $13,216,581.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joseph E. Gilliam sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $129.36, for a total value of $646,800.00. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $13,216,581.84. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,275 shares of company stock worth $1,354,967. 6.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on GKOS shares. Needham & Company LLC lifted their price objective on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Truist Financial boosted their price target on shares of Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler set a $140.00 price objective on shares of Glaukos in a research note on Thursday, October 17th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, BTIG Research increased their target price on Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.